Reported about 6 hours ago
Danish pharmaceutical company Novo Nordisk reported strong financial results for 2024, driven by impressive sales of its weight loss and diabetes medications, Wegovy and Ozempic, generating combined revenue of $24.9 billion. While the company exceeded Wall Street forecasts with a 25% increase in full-year revenue to $40.5 billion, it anticipates slower growth in 2025 compared to the previous year. Despite challenges, including a competitive landscape and marketing negotiations with Medicare, Novo Nordisk remains a leading player in the weight loss sector.
Source: YAHOO